Phreesia

AI Integration And Digital Adoption Will Expand Healthcare Services

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

27 May 25

Updated

06 Sep 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-6.6%

-1.0%

-6.6%

-1.0%

You can edit this narrative until Sep 7 10:11 AM. Then, changes will post as Updates.

Author's Valuation

US$33.7339.9% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on 06 Sep 25

Fair value Increased 3.90%

Phreesia’s price target increased to $33.73 as analysts responded positively to solid Q2 results, upwardly revised FY26 EBITDA guidance, strategic product launches, and the AccessOne acquisition—despite valuation concerns—supporting a strong double-digit growth outlook and margin expansion. Analyst Commentary Solid Q2 results, with revenues in line and adjusted EBITDA ahead of consensus; company raised FY26 EBITDA guidance driven by effective expense management.

AnalystConsensusTarget Fair Value

US$33.73

39.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

12.88%

Healthtech revenue growth rate

10.95%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.21%

Calculation

US$52.28m

Earnings '28

53.39x

PE Ratio '28

US$2.79b

Market Cap '28

US$2.79b

Market Cap '28

66.18m

No. shares '28

US$42.18

Share Price '28

US$42.18 Share Price '28

Discounted to 2025 @ 7.83% p.a.

US$33.64

Fair Value '25